Development and Evaluation of the Atherosclerosis and Metabolic Risk Score Using Data from the National Health and Nutrition Examination Survey

Kaftan, Ahmed Naseer; Aljabery, Hasanat

doi:10.33091/amj.2026.169181.2592

	Development and Evaluation of the Atherosclerosis and Metabolic Risk Score Using Data from the National Health and Nutrition Examination Survey
Al- Anbar Medical Journal
Volume 22, Issue 3, July 2026, Pages 171-177 PDF (2.3 M)
Document Type: Original articles
DOI: 10.33091/amj.2026.169181.2592
Authors
Ahmed Naseer Kaftan^* ; Hasanat Aljabery
Department of Biochemistry, Faculty of Medicine, University of Kufa, Najaf, Iraq.
Abstract
Background: Metabolic disorders are major contributors to cardiovascular morbidity and premature mortality worldwide. Conventional clinical assessment approaches typically evaluate individual metabolic parameters separately and may not adequately capture the complex interactions among metabolic pathways. Objectives: To develop and evaluate the atherosclerosis and metabolic risk score (AMRS), a composite logarithmic index integrating anthropometric, biochemical, and demographic variables to quantify metabolic burden and classify individuals with metabolic abnormalities. Materials and Methods: A cross-sectional design included 8,402 adults aged 18-85 years from the public-use database of the NHANES [National Health and Nutrition Examination Survey] (2016-2017). The AMRS was calculated as a log-linear combination of nine clinical variables including: age, sex, body mass index (BMI), systolic and diastolic blood pressure (SBP, DBP), triglycerides (TG), total cholesterol (TC), fasting blood glucose (FBG), and HbA1c. Model performance was assessed using ROC curve analysis, subgroup analysis, risk stratification using percentiles, and chi-squared tests. To test the discriminative power of the model, sensitivity analyses were conducted by excluding one outcome-defining variable at a time from the AMRS formula. An external validation was also performed using an independent NHANES 2013-2014 cohort. Results: AMRS demonstrated good discrimination against glycemic abnormalities and moderate discrimination for lipid and blood pressure disorders. Area under curve values were 0.81 for hyperglycemia, 0.81 for elevated HbA1c, 0.73 for hypertriglyceridemia, 0.71 for hypercholesterolemia, and 0.72 for hypertension. Sensitivity analyses demonstrated that the score retained moderate discriminatory ability even after the removal of outcome-defining variables. External validation showed consistent discrimination across outcomes. Conclusion: The AMRS provides an integrated quantitative measure of cardiometabolic burden by combining multiple metabolic domains into a single composite index. The score demonstrated stable discrimination and robustness across analyses and may support population-level metabolic risk stratification and classification of metabolic burden.
Keywords
Diabetes Mellitus; Hypertension; Dyslipidemias; Cardiometabolic predictor

References
[1] N. W. Chew et al., "The global burden of metabolic disease: Data from 2000 to 2019," Cell metabolism, vol. 35, no. 3, pp. 414-428. e3, 2023. [2] A. A. Algenabi, A. N. Kaftan, M. K. Hussain, F. A. Wdaah, and F. H. Naser, "The impact of promoter single nucleotide polymorphism (-11391 G/A) on type II diabetes mellitus in Iraqi population," Gene Reports, vol. 23, p. 101115, 2021. [3] K. G. M. Alberti, P. Zimmet, and J. Shaw, "The metabolic syndrome—a new worldwide definition," The Lancet, vol. 366, no. 9491, pp. 1059-1062, 2005. [4] T. M. Powell-Wiley et al., "Obesity and cardiovascular disease: a scientific statement from the American Heart Association," Circulation, vol. 143, no. 21, pp. e984-e1010, 2021. [5] Y. Sun, H. Ji, W. Sun, X. An, and F. Lian, "Triglyceride glucose (TyG) index: A promising biomarker for diagnosis and treatment of different diseases," European journal of internal medicine, vol. 131, pp. 3-14, 2025. [6] S. Iturbe-Rey et al., "Lipotoxicity-driven metabolic dysfunction-associated steatotic liver disease (MASLD)," Atherosclerosis, vol. 400, p. 119053, 2025. [7] J. F. Cohen and P. M. Bossuyt, "TRIPOD+ AI: an updated reporting guideline for clinical prediction models," vol. 385, ed: British Medical Journal Publishing Group, 2024. [8] M. Miller et al., "Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association," Circulation, vol. 123, no. 20, pp. 2292-2333, 2011. [9] D. Care, "2. Diagnosis and classification of diabetes: Standards of care in diabetes—2024," Diabetes Care, vol. 47, no. Suppl 1, pp. S20-s42, 2024. [10] S. M. Grundy et al., "2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines," Journal of the American College of Cardiology, vol. 73, no. 24, pp. e285-e350, 2019. [11] F. Guerrero-Romero et al., "The product of triglycerides and glucose, a simple measure of insulin sensitivity. Comparison with the euglycemic-hyperinsulinemic clamp," The Journal of Clinical Endocrinology & Metabolism, vol. 95, no. 7, pp. 3347-3351, 2010. [12] P. W. Wilson, R. B. D’Agostino, D. Levy, A. M. Belanger, H. Silbershatz, and W. B. Kannel, "Prediction of coronary heart disease using risk factor categories," Circulation, vol. 97, no. 18, pp. 1837-1847, 1998. [13] Q. Sun et al., "Cardiometabolic Index (CMI), Lipid Accumulation Products (LAP), Waist Triglyceride Index (WTI) and the risk of acute pancreatitis: a prospective study in adults of North China," Lipids in health and disease, vol. 22, no. 1, p. 190, 2023. [14] H. S. Kahn, "The" lipid accumulation product" performs better than the body mass index for recognizing cardiovascular risk: a population-based comparison," BMC cardiovascular disorders, vol. 5, no. 1, p. 26, 2005. [15] National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. vol. 106(25):3143-421, 2002. [16] M. Riddle, G. Bakris, and L. Blonde, "Standards of medical care in diabetes-2020," Diabetes Care, vol. 43, no. 8, pp. 1980-1980, 2020. [17] A. V. Chobanian et al., "Seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure," hypertension, vol. 42, no. 6, pp. 1206-1252, 2003. [18] P. C. Chandler‐Laney et al., "Age‐related changes in insulin sensitivity and β‐cell function among European‐American and African‐American women," Obesity, vol. 19, no. 3, pp. 528-535, 2011. [19] V. Regitz-Zagrosek, E. Lehmkuhl, and S. Mahmoodzadeh, "Gender aspects of the role of the metabolic syndrome as a risk factor for cardiovascular disease," Gender medicine, vol. 4, pp. S162-S177, 2007. [20] A. Liu, F. Abbasi, and G. Reaven, "Adiposity indices in the prediction of metabolic abnormalities associated with cardiovascular disease in non-diabetic adults," Nutrition, Metabolism and Cardiovascular Diseases, vol. 21, no. 8, pp. 553-560, 2011. [21] E. J. Enichen, K. Heydari, and J. C. Kvedar, "Assessing alternative strategies for measuring metabolic risk," npj Digital Medicine, vol. 7, no. 1, p. 360, 2024. [22] O. Efthimiou, M. Seo, K. Chalkou, T. Debray, M. Egger, and G. Salanti, "Developing clinical prediction models: a step-by-step guide," Bmj, vol. 386 :e078276, 2024. [23] E. Domingo, P. Marques, V. Francisco, L. Piqueras, and M.-J. Sanz, "Targeting systemic inflammation in metabolic disorders. A therapeutic candidate for the prevention of cardiovascular diseases?," Pharmacological research, vol. 200, p. 107058, 2024. [24] F. Mauvais-Jarvis, "Sex differences in energy metabolism: natural selection, mechanisms and consequences," Nature Reviews Nephrology, vol. 20, no. 1, pp. 56-69, 2024. [25] N. Stefan and M. B. Schulze, "Metabolic health and cardiometabolic risk clusters: implications for prediction, prevention, and treatment," The lancet Diabetes & endocrinology, vol. 11, no. 6, pp. 426-440, 2023.
Statistics Article View: 273 PDF Download: 237